Search Results Search Sort by RelevanceMost Recent Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105. Viewpoint Apr 2014 Inappropriate Obstructions to Access: The FDA’s Handling of Plan B Susan F. Wood, PhD The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions. Virtual Mentor. 2014;16(4):295-301. doi: 10.1001/virtualmentor.2014.16.4.oped1-1404. Viewpoint Apr 2015 Making Ethical Progress without Ethical Theories Dien Ho, PhD AMA J Ethics. 2015;17(4):289-296. doi: 10.1001/journalofethics.2015.17.4.spec1-1504. State of the Art and Science Oct 2019 Should Clinicians Leave “Expanded” Carrier Screening Decisions to Patients? Amanda Fakih, MHSA and Kayte Spector-Bagdady, JD, MBE Testing everyone for everything identifies more fetal conditions, but confusion persists about whether clinicians should leave screening decisions to patients. AMA J Ethics. 2019;21(10):E858-864. doi: 10.1001/amajethics.2019.858.